Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Tuñón, José ^a,b   Cristóbal, Carmen ^c,d   Tarín, Nieves ^e   Aceña, Álvaro ^a   González Casaus, María Luisa ^f   Huelmos, Ana ^g   Alonso, Joaquín ^c,d   Lorenzo, Óscar ^a,b   González Parra, Emilio ^a,b   Mahíllo Fernández, Ignacio ^a   Pello, Ana María ^a   Carda, Rocío ^a   Farré, Jerónimo ^a,b   Rodríguez Artalejo, Fernando ^b   López Bescós, Lorenzo ^d   Egido, Jesús ^a,b,h  

^a 28400 Madrid   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^d UNIVERSIDAD REY JUAN CARLOS   (Spain)

^e HOSPITAL DE MÓSTOLES   (Spain)

^f HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^g HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINERAL METABOLISM; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VITAMIN BLOOD LEVEL; BLOOD; PROGNOSIS;

AGED; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; VITAMIN D;

EID: 84899697548     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095402     Document Type: Article

References (36)

1. Ketteler M, Wolf M, Hahn K, Ritz E (2013) Phosphate: a novel cardiovascular risk factor. Eur Heart J 34: 1099-1101.
2. Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21: 1427-1435.
3. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, et al. (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408.
4. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, et al. (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 152: 640-648.
5. Lavie CJ, Lee JH, Milani RV (2011) Vitamin D and cardiovascular disease will it live up to its hype? J Am Coll Cardiol 58: 1547-1556.
6. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R (1990) Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 19: 559-563. (Pubitemid 20331800)
7. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, et al. (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 104: 16810-16815. (Pubitemid 350210947)
8. Wu J, Garami M, Cheng T, Gardner DG (1996) 1,25 (OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 97: 1577-1588. (Pubitemid 26105467)
9. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-847.
10. Holick M (2008) Vitamin D and Sunlight: Strategies for Cancer Prevention and other Health Benefits. Clin J Am Soc Nephrol 3: 1548-1554.
11. Wang L, Song Y, Manson JE, Pilz S, Mä rz W, et al. (2012) Circulating 25-hydroxy-vitamin d and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 5: 819-829.
12. Grandi NC, Breitling LP, Brenner H (2010) Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev Med 51: 228-233.
13. Brøndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG. (2012) 25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol 32: 2794-2802.
14. Syal SK, Kapoor A, Bhatia E, Sinha A, Kumar S, et al. (2012) Vitamin D deficiency, coronary artery disease, and endothelial dysfunction: observations from a coronary angiographic study in Indian patients. J Invasive Cardiol 24: 385-389.
15. Chen WR, Qian YA, Chen YD, Shi Y, Yin DW, et al. (2013) The Effects of Low Vitamin D on Coronary Artery Disease. Heart Lung Circ Sep 3. pii: S1443-9506 (13) 01162-1. doi:10.1016/j.hlc.2013.08.012. [Epub ahead of print].
16. Karakas M, Thorand B, Zierer A, Huth C, Meisinger C, et al. (2013) Low Levels of Serum 25-Hydroxyvitamin D Are Associated with Increased Risk of Myocardial Infarction, Especially in Women: Results from the MONICA/KORA Augsburg Case-Cohort Study. J Clin Endocrinol Metab 98: 272-280.
17. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, et al. (1997) Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96: 1755-1760. (Pubitemid 27400730)
18. De Borst MH, Vervloet MG, ter Wee PM, Navis G (2011) Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 22: 1603-1609.
19. Gonzalez-Parra E, Rojas-Rivera J, Tuñón J, Praga M, Ortiz A, et al. (2012) Vitamin D receptor activation and cardiovascular disease. Nephrol Dial Transplant 27 (Suppl 4): 17-21.
20. Siasos G, Tousoulis D, Oikonomou E, Maniatis K, Kioufis S, et al. (2013) Vitamin D serum levels are associated with cardiovascular outcome in coronary artery disease. Int J Cardiol 168: 4445-4447.
21. Bittner V, Wenger NK, Waters DD, DeMicco DA, Messig M, et al. (2012) Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease. Am Heart J 164: 387-393.
22. Emberson J, Bennett D, Link E, Parish S, Danesh J, et al. (2011) C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377: 469-476.
23. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, et al. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568. (Pubitemid 38542505)
24. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, et al. (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Eng J Med 359: 584-592.
25. Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating FGF-23 is associated with vascular dysfunction in the community. Atherosclerosis 205: 385-390.
26. Mirza MA, Hansen T, Johansson L, Ahlström H, Larsson A, et al. (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24: 3125-3131.
27. Masai H, Joki N, Sugi K, Moroi M (2013) A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease. Atherosclerosis 226: 228-233.
28. Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, et al. (2013) Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 83: 160-166.
29. Scialla JJ, Ling Lau W, Reilly MP, Isakova T, Yang HY, et al. (2013) Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83: 1159-1168.
30. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC (2011) Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 161: 956-962.
31. Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, et al. (2012) Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7: 810-819.
32. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, et al. (2012) Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis 60: 567-575.
33. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, et al. (2007) Calcium/vitamin D supplementation and cardiovascular events. Circulation 115: 846-854. (Pubitemid 46294725)
34. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, et al. (2011) Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 96: 1931-1942.
35. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, et al. (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307: 674-684.
36. Tang WJ, Wang LF, Xu XY, Zhou Y, Jin WF, et al. (2010) Autocrine/paracrine action of vitamin D on FGF23 expression in cultured rat osteoblasts. Calcif Tissue Int 86: 404-410.